166 related articles for article (PubMed ID: 35871905)
21. Functioning gonadotroph adenoma with severe ovarian hyperstimulation syndrome: A new emergency in pituitary adenoma surgery? Surgical considerations and literature review.
Graillon T; Castinetti F; Chabert-Orsini V; Morange I; Cuny T; Albarel F; Brue T; Dufour H
Ann Endocrinol (Paris); 2019 Apr; 80(2):122-127. PubMed ID: 30825998
[TBL] [Abstract][Full Text] [Related]
22. Gonadotroph Pituitary Adenoma Causing Treatable Infertility and Ovarian Hyperstimulation Syndrome in Female Patients: Neurosurgical, Endocrinologic, Gynecologic, and Reproductive Outcomes.
Hasegawa H; Nesvick CL; Erickson D; Cohen SC; Yolcu YU; Khan Z; Raghunathan A; Nippoldt TB; Atkinson JL; Van Gompel JJ
World Neurosurg; 2021 Jun; 150():e162-e175. PubMed ID: 33684575
[TBL] [Abstract][Full Text] [Related]
23. Gonadotroph adenomas.
Samuels MH
Curr Ther Endocrinol Metab; 1994; 5():52-6. PubMed ID: 7704786
[No Abstract] [Full Text] [Related]
24. [Clinically non functioning pituitary adenomas and gonadotroph-cell adenomas].
Caron P
Presse Med; 2009 Jan; 38(1):103-6. PubMed ID: 18990542
[TBL] [Abstract][Full Text] [Related]
25. Updating the Landscape for Functioning Gonadotroph Tumors.
Ntali G; Capatina C
Medicina (Kaunas); 2022 Aug; 58(8):. PubMed ID: 36013538
[TBL] [Abstract][Full Text] [Related]
26. Medical therapy of gonadotropin-producing and nonfunctioning pituitary adenomas.
Shomali ME; Katznelson L
Pituitary; 2002; 5(2):89-98. PubMed ID: 12675506
[TBL] [Abstract][Full Text] [Related]
27. Pituitary tumor transforming gene and insulin-like growth factor 1 receptor expression and immunohistochemical measurement of Ki-67 as potential prognostic markers of pituitary tumors aggressiveness.
Sánchez-Tejada L; Sánchez-Ortiga R; Moreno-Pérez O; Montañana CF; Niveiro M; Tritos NA; Alfonso AM
Endocrinol Nutr; 2013; 60(7):358-67. PubMed ID: 23416216
[TBL] [Abstract][Full Text] [Related]
28. 'Silent' somatotropinoma.
Pawlikowski M; Kuta J; Fuss-Chmielewska J; Winczyk K
Endokrynol Pol; 2012; 63(2):88-91. PubMed ID: 22538745
[TBL] [Abstract][Full Text] [Related]
29. Results of somatostatin receptor scintigraphy do not predict pituitary tumor volume- and hormone-response to ocreotide therapy and do not correlate with tumor histology.
Plöckinger U; Bäder M; Hopfenmüller W; Saeger W; Quabbe HJ
Eur J Endocrinol; 1997 Apr; 136(4):369-76. PubMed ID: 9150695
[TBL] [Abstract][Full Text] [Related]
30. Clinical characteristics and outcomes of null-cell versus silent gonadotroph adenomas in a series of 1166 pituitary adenomas from a single institution.
Haddad AF; Young JS; Oh T; Pereira MP; Joshi RS; Pereira KM; Osorio RC; Donohue KC; Peeran Z; Sudhir S; Jain S; Beniwal A; Chopra AS; Sandhu NS; Theodosopoulos PV; Kunwar S; El-Sayed IH; Gurrola J; Blevins LS; Aghi MK
Neurosurg Focus; 2020 Jun; 48(6):E13. PubMed ID: 32480370
[TBL] [Abstract][Full Text] [Related]
31. Multimodal Non-Surgical Treatments of Aggressive Pituitary Tumors.
Nakano-Tateno T; Lau KJ; Wang J; McMahon C; Kawakami Y; Tateno T; Araki T
Front Endocrinol (Lausanne); 2021; 12():624686. PubMed ID: 33841328
[TBL] [Abstract][Full Text] [Related]
32. Prognostic factors of regrowth in nonfunctioning pituitary tumors.
Raverot G; Vasiljevic A; Jouanneau E
Pituitary; 2018 Apr; 21(2):176-182. PubMed ID: 29288467
[TBL] [Abstract][Full Text] [Related]
33. Subclinical hyperfunctioning pituitary adenomas: the silent tumors.
Cooper O; Melmed S
Best Pract Res Clin Endocrinol Metab; 2012 Aug; 26(4):447-60. PubMed ID: 22863387
[TBL] [Abstract][Full Text] [Related]
34. [Treatment of clinically nonfunctioning pituitary adenomas].
Alameda Hernando C; Lahera Vargas M; Varela Da Costa C
Endocrinol Nutr; 2010 Feb; 57(2):71-81. PubMed ID: 20227355
[TBL] [Abstract][Full Text] [Related]
35. Postoperative treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists decreases tumour remnant growth.
Greenman Y; Tordjman K; Osher E; Veshchev I; Shenkerman G; Reider-Groswasser II; Segev Y; Ouaknine G; Stern N
Clin Endocrinol (Oxf); 2005 Jul; 63(1):39-44. PubMed ID: 15963059
[TBL] [Abstract][Full Text] [Related]
36. New technique for quantitation of pituitary adenoma size: use in evaluating treatment of gonadotroph adenomas with a gonadotropin-releasing hormone antagonist.
McGrath GA; Goncalves RJ; Udupa JK; Grossman RI; Pavlou SN; Molitch ME; Rivier J; Vale WW; Snyder PJ
J Clin Endocrinol Metab; 1993 May; 76(5):1363-8. PubMed ID: 8496331
[TBL] [Abstract][Full Text] [Related]
37. [Pituitary carcinomas and aggressive adenomas: an overview and new therapeutic options].
Maïza JC; Caron P
Ann Endocrinol (Paris); 2009 Sep; 70 Suppl 1():S12-9. PubMed ID: 19878763
[TBL] [Abstract][Full Text] [Related]
38. Follicle-stimulating hormone-secreting pituitary adenoma manifesting as recurrent ovarian cysts in a young woman--latent risk of unidentified ovarian hyperstimulation: a case report.
Kawaguchi T; Ogawa Y; Ito K; Watanabe M; Tominaga T
BMC Res Notes; 2013 Oct; 6():408. PubMed ID: 24119690
[TBL] [Abstract][Full Text] [Related]
39. Immunohistochemical detection of somatostatin receptor subtypes in "clinically nonfunctioning" pituitary adenomas.
Pawlikowski M; Pisarek H; Kunert-Radek J; Radek A
Endocr Pathol; 2003; 14(3):231-8. PubMed ID: 14586068
[TBL] [Abstract][Full Text] [Related]
40. Effects of somatostatin-14 and the receptor-specific somatostatin analogs on chromogranin A and alpha-subunit (alpha-SU) release from "clinically nonfunctioning" pituitary adenoma cells incubated in vitro.
Pawlikowski M; Lawnicka H; Pisarek H; Kunert-Radek J; Radek M; Culler MD
J Physiol Pharmacol; 2007 Mar; 58(1):179-88. PubMed ID: 17440235
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
